We are live on
!
Find out more
AAP
Ardsley Advisory Partners Portfolio holdings
AUM
$960M
1-Year Est. Return
207.76%
This Fund
S&P 500
This Quarter
Est. Return
+19.58%
1 Year Est. Return
+207.76%
3 Year Est. Return
+554.53%
5 Year Est. Return
+728.66%
10 Year Est. Return
+4,084.52%
AUM
$521M
AUM Growth
+$123M
(+31%)
Cap. Flow
+$74M
Cap. Flow
% of AUM
14.2%
Top 10 Holdings %
Top 10 Hldgs %
42.06%
Holding
160
New
57
Increased
37
Reduced
27
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$11.3M |
| 2 |
Amazon
AMZN
|
+$11.3M |
| 3 |
EVA
Enviva Inc.
EVA
|
+$10.5M |
| 4 |
Medifast
MED
|
+$10.1M |
| 5 |
CTLP
Cantaloupe
CTLP
|
+$8.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$13.6M |
| 2 |
CVS Health
CVS
|
+$12.8M |
| 3 |
Sunrun
RUN
|
+$11M |
| 4 |
Adobe
ADBE
|
+$10.1M |
| 5 |
ServiceNow
NOW
|
+$8.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.67% |
| 2 | Industrials | 16.23% |
| 3 | Healthcare | 15.24% |
| 4 | Consumer Discretionary | 7.69% |
| 5 | Consumer Staples | 4.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Option Care Health
OPCH
$3.53B
| $50K | 0.01% |
6,250
-18,750
| -75% | -$247K |
|
127
GE Aerospace
GE
$377B
| $40K | 0.01% |
+803
| New | +$37.8K |
|
128
Actinium Pharmaceuticals
ATNM
$27.2M
| $36K | 0.01% |
2,500
-167
| -6% | -$2.67K |
|
|
CORV
129
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $33K | 0.01% |
+10,366
| New | +$33.5K |
|
130
VistaGen Therapeutics
VTGN
$9.55M
| $32K | 0.01% |
+833
| New | +$36.3K |
|
|
CARM
131
DELISTED
Carisma Therapeutics
CARM
| $21K | ﹤0.01% |
+1,025
| New | +$17.7K |
|
132
AtriCure
ATRC
$2.02B
| – | – |
-15,000
| Closed | -$459K |
|
133
Becton Dickinson
BDX
$45.8B
| – | – |
-2,563
| Closed | -$563K |
|
134
Cigna
CI
$79.6B
| – | – |
-6,000
| Closed | -$1.14M |
|
|
135
CVS Health
CVS
$140B
| – | – |
-195,000
| Closed | -$12.8M |
|
136
Darling Ingredients
DAR
$9.28B
| – | – |
-50,000
| Closed | -$962K |
|
137
Dropbox
DBX
$7.48B
| – | – |
-14,000
| Closed | -$286K |
|
138
Encompass Health
EHC
$11.5B
| – | – |
-6,285
| Closed | -$309K |
|
139
Goldman Sachs
GS
$305B
| – | – |
-10,000
| Closed | -$1.67M |
|
|
140
Jazz Pharmaceuticals
JAZZ
$16.1B
| – | – |
-110,000
| Closed | -$13.6M |
|
|
LITS
141
Lite Strategy Inc
LITS
$33M
| – | – |
-1,603
| Closed | -$85K |
|
142
Magnite
MGNI
$2.82B
| – | – |
-65,000
| Closed | -$242K |
|
143
Merck
MRK
$326B
| – | – |
-6,288
| Closed | -$458K |
|
144
Rapid7
RPD
$642M
| – | – |
-23,000
| Closed | -$717K |
|
145
SPS Commerce
SPSC
$2.51B
| – | – |
-18,000
| Closed | -$741K |
|
146
United Rentals
URI
$67.9B
| – | – |
-15,000
| Closed | -$1.54M |
|
147
Valero Energy
VLO
$88.7B
| – | – |
-65,000
| Closed | -$4.87M |
|
148
Vertex Pharmaceuticals
VRTX
$124B
| – | – |
-2,000
| Closed | -$331K |
|
149
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| – | – |
-125,000
| Closed | -$8.97M |
|
150
Zscaler
ZS
$24.5B
| – | – |
-12,000
| Closed | -$471K |
|
Similar funds
NA
MK
QIM
JVBC
TFP
UWPG
LOAMU
PHS
Ardsley Advisory Partners's Q1 2019 Portfolio in Review
As of Q1 2019, Ardsley Advisory Partners held 160 positions worth $521M, up 31% from $398M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Ardsley Advisory Partners deployed $74M of net new capital in Q1 2019, opening 57 new positions and adding to 37 existing holdings. Its largest new stake was Medifast: 80,000 shares worth $10.2M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 30% a quarter earlier, followed by Industrials and Healthcare.
On the sell side, the largest reduction was Sunrun, an estimated $11M trimmed.
- Ardsley Advisory Partners's largest Q1 2019 buy was Medifast: 80,000 shares worth $10.2M.
- Ardsley Advisory Partners added most to Celgene Corp in Q1 2019, an estimated $11.3M increase.
- Ardsley Advisory Partners's biggest Q1 2019 reduction was Sunrun, cutting an estimated $11M.
- Ardsley Advisory Partners fully exited Jazz Pharmaceuticals in Q1 2019, selling an estimated $13.6M.
- Ardsley Advisory Partners's ten largest holdings make up 42% of its $521M portfolio in Q1 2019.
- Ardsley Advisory Partners opened 57 new positions and closed 29 in Q1 2019.
- Ardsley Advisory Partners's portfolio value rose 31% quarter-over-quarter to $521M.
Based on Ardsley Advisory Partners's 13F filing for Q1 2019, filed 15 May 2019.